Incyte Corporation (NASDAQ:INCY) went up by 1.54% from its latest closing price compared to the recent 1-year high of $110.36. The company’s stock price has collected 5.59% of gains in the last five trading sessions. Press Release reported on 06/08/21 that Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi(R) ) in Chronic Graft-Versus-Host Disease (GVHD)
Is It Worth Investing in Incyte Corporation (NASDAQ :INCY) Right Now?
Incyte Corporation (NASDAQ:INCY) scored a price-to-earnings ratio above its average ratio, recording 40.30 x from its present earnings ratio. Plus, the 36-month beta value for INCY is at 0.80. Opinions of the stock are interesting as 10 analysts out of 20 who provided ratings for Incyte Corporation declared the stock was a “buy,” while 1 rated the stock as “overweight,” 8 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $106.21, which is $18.85 above the current price. INCY currently public float of 216.74M and currently shorts hold a 2.25% ratio of that float. Today, the average trading volume of INCY was 1.15M shares.
INCY’s Market Performance
INCY stocks went up by 5.59% for the week, with a monthly jump of 8.54% and a quarterly performance of 10.13%, while its annual performance rate touched -5.92%. The volatility ratio for the week stands at 2.46% while the volatility levels for the past 30 days are set at 2.29% for Incyte Corporation. The simple moving average for the period of the last 20 days is 5.27% for INCY stocks with a simple moving average of 1.94% for the last 200 days.
Analysts’ Opinion of INCY
Many brokerage firms have already submitted their reports for INCY stocks, with SVB Leerink repeating the rating for INCY by listing it as a “Underperform.” The predicted price for INCY in the upcoming period, according to SVB Leerink is $70 based on the research report published on February 10th of the current year 2021.
Truist, on the other hand, stated in their research note that they expect to see INCY reach a price target of $120. The rating they have provided for INCY stocks is “Buy” according to the report published on January 07th, 2021.
INCY Trading at 5.54% from the 50-Day Moving Average
After a stumble in the market that brought INCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.69% of loss for the given period.
Volatility was left at 2.29%, however, over the last 30 days, the volatility rate increased by 2.46%, as shares surge +6.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.10% upper at present.
During the last 5 trading sessions, INCY rose by +5.59%, which changed the moving average for the period of 200-days by -6.92% in comparison to the 20-day moving average, which settled at $83.41. In addition, Incyte Corporation saw 0.63% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at INCY starting from Dhanak Dashyant, who sale 395 shares at the price of $84.13 back on Jun 01. After this action, Dhanak Dashyant now owns 26,545 shares of Incyte Corporation, valued at $33,231 using the latest closing price.
Dhanak Dashyant, the EVP & Chief Scientific Officer of Incyte Corporation, sale 396 shares at $81.57 during a trade that took place back on Apr 01, which means that Dhanak Dashyant is holding 27,336 shares at $32,302 based on the most recent closing price.
Stock Fundamentals for INCY
Current profitability levels for the company are sitting at:
- -9.01 for the present operating margin
- +93.94 for the gross margin
The net margin for Incyte Corporation stands at -11.09. The total capital return value is set at -8.99, while invested capital returns managed to touch -11.16. Equity return is now at value 19.00, with 13.90 for asset returns.
Based on Incyte Corporation (INCY), the company’s capital structure generated 2.36 points at debt to equity in total, while total debt to capital is 2.31. Total debt to assets is 1.72, with long-term debt to equity ratio resting at 1.79. Finally, the long-term debt to capital ratio is 1.75.
When we switch over and look at the enterprise to sales, we see a ratio of 6.46, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 6.74 and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.